Items Tagged ‘Melanoma’

October 24th, 2016

Yervoy® Improves Overall Survival in Fully Resected Stage III Melanoma Patients

By

Results were presented during the 2016 European Society for Medical Oncology Congress demonstrating that Yervoy® (ipilimumab) compared to placebo improves survival in stage III melanoma patients who are at high risk of recurrence following complete surgical resection. In the study, Yervoy compared with placebo significantly improved overall survival (OS) with five-year OS rates at 65.4% […]

View full entry

Tags: 2016, advanced melanoma, ESMO, high-risk, ipilimumab, Melanoma, News, overall survival, stage III, Stage III Melanoma, Yervoy


October 11th, 2016

Epacadostat Plus Keytruda® Appears Effective in Melanoma

By

The treatment combination consisting of epacadostat plus Keytruda® (pembrolizumab) appears effective in the treatment of advanced melanoma. Melanoma is a type of skin cancer that often starts in the form of a mole. If detected and treatable with surgery, melanoma has a high cure rate. However, once melanoma invades deeper tissues or spreads from its […]

View full entry

Tags: advanced, Epacadostat, keytruda, Melanoma, mole, News, Skin Cancer, Stage III Melanoma, Stage IV Melanoma


September 20th, 2016

Cotellic®/Zelboraf® Combo: New Standard of Care for Melanoma

By

The treatment combination consisting of Cotellic® (cobimetinib) plus Zelboraf® (vemurafenib) improves overall survival for patients with advanced, BRAF (V600) mutation-positive melanoma. These confirmatory results have led to this treatment combination being considered as a new standard of care for patients with this disease. These results were recently published in the Lancet Oncology. Melanoma is a […]

View full entry

Tags: advanced, BRAF V600, cobimetinib, combination, Melanoma, metastatic, News, Stage III Melanoma, Stage IV Melanoma, vemurafenib


July 21st, 2016

3-Year Survival Improved with Taflinar®/Mekinist® Combination in Advanced Melanoma

By

Patients with advanced melanoma who were treated with the combination consisting of Taflinar (dabrafenib) plus Mekinist (trametinib) had a significantly improved survival rate at 3 years compared to those treated with Taflinar only. These results were presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Advanced melanoma refers to skin […]

View full entry

Tags: 2016, advanced, asco, BRAFV600E/K mutation, COMBI-d trial, dabrafenib, kinase inhibitors, mekinist, Melanoma, News, Stage IV Melanoma, Taflinar


May 25th, 2016

Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk

By

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing and genetic counseling service, today announced its expansion into the oncology market, with a focus on advancing cancer risk screening and helping cancer prevention efforts. Counsyl’s […]

View full entry

Tags: asco, ASCO16, ASCO2016, BRCAtesting, breast, Breast Cancer, breastcancerawareness, colon, Colon Cancer, DNAtesting, genetic testing, inherited cancer screen


December 2nd, 2015

Opdivo Receives Expanded Approval as Single Agent for Initial Therapy in Melanoma

By

The United States Food and Drug Administration (FDA) has approved the PD1 inhibitor, Opdivo (nivolumab), as a single agent for initial therapy of advanced melanoma. This is the sixth indication for which Opdivo has been approved in the past 12 months. The indication for this expanded approval specifies that Opdivo can be used for treatment […]

View full entry

Tags: advanced, CheckMate -066 trial, Melanoma, metastatic, News, opdivo, Skin Cancer, Stage III Melanoma, Stage IV Melanoma


November 9th, 2015

Yervoy Gets Expanded Approval for Earlier-Stage Melanoma

By

The United States Food and Drug Administration (FDA) has expanded the approval indication for Yervoy (ipilimumab) to include treatment of stage III melanoma. Melanoma is the most deadly form of skin cancer, as it is more likely than other forms of skin cancer to spread from its site of origin to other sites in the […]

View full entry

Tags: Melanoma, News, Recurrent Melanoma, Stage III Melanoma


October 28th, 2015

Imlygic® Approved for Melanoma

By

Imlygic® (talimogene laherparepvec), the first ever FDA-approved oncolytic virus therapy, has been approved for the treatment of melanoma. The approval is for the treatment of melanoma sites in the skin and lymph nodes that cannot be surgically removed. Imlygic is given as an injection directly into the site of cancer, and is given through a […]

View full entry

Tags: Imylgic, Melanoma, News, oncolytic virus therapy, talimogene laherparepvec


June 29th, 2015

Opdivo® Alone or Combined with Yervoy® Effective in Advanced Melanoma

By

Opdivo® (nivolumab) used alone or in combination with Yervoy® (ipilimumab) appears to extend progression-free survival in patients with advanced melanoma. These findings were presented at 2015 Annual Meeting of the American Society of Clinical Oncology (May 29–June 2, Chicago, Illinois) and published in the New England Journal of Medicine. Standard treatment for advanced melanoma typically […]

View full entry

Tags: advanced melanoma, ipilimumab, Melanoma, News, nivolumab, opdivo, Stage III Melanoma, Stage IV Melanoma, Yervoy


May 1st, 2015

Melanoma Drug T-VEC Receives Recommendation for FDA Approval

By

An advisory panel to the U.S. Food and Drug Administration (FDA) has recommended approval of the investigational drug T-VEC (talimogene laherparepvec) for the treatment of metastatic melanoma. Biopharmaceutical company Amgen recently announced plans to move forward with approval process.[1] The recommendation for approval is based on findings from a Phase III clinical trial in which […]

View full entry

Tags: fda, Melanoma, News, Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma, T-VEC


April 20th, 2015

Keytruda® May Be More Effective than Yervoy® in Advanced Melanoma

By

Keytruda® (pembrolizumab) appears to outperform Yervoy® (ipilimumab) at initial treatment of patients with advanced melanoma. Pharmaceutical company Merck announced these Phase III clinical trial findings in a press release in March 2015. Melanoma is less common than non-melanoma skin cancer, but tends to be much more aggressive. What makes melanoma so dangerous is that it […]

View full entry

Tags: advanced melanoma, ipilimumab, KEYNOTE-006, keytruda, Melanoma, News, pembrolizumab, Stage III Melanoma, Stage IV Melanoma, Yervoy


February 6th, 2015

Yervoy® Improves Treatment of Stage III Melanoma

By

CancerConnect News: The first trial of the immunomodulator Yervoy® (ipilimumab) conducted in patients with stage III melanoma appears promising, demonstrating an improvement by delaying cancer recurrence and improving survival. Skin cancer is the most common form of cancer in the United States, with more than one million new cases each year. Skin cancer is often […]

View full entry

Tags: ipilimumab, Melanoma, News, stage 3 melanoma, Stage III Melanoma, Yervoy


February 2nd, 2015

Coffee May Decrease Risk of Melanoma Skin Cancer

By

Coffee might do more than perk you up. New research suggests that coffee drinkers are less likely to develop malignant melanoma, and their risk decreases with every cup they drink.1 Coffee has long been associated with a reduction in the risk of various cancers however the current study is the first to show a reduction […]

View full entry

Tags: coffee, Melanoma, melanoma prevention, News, Recurrent Melanoma, Stage IV Melanoma


December 23rd, 2014

FDA Approves Nivolumab for Advanced Melanoma

By

The FDA granted accelerated approval to nivolumab (Opdivo) for patients with unresectable or metastatic melanoma who no longer respond to other drugs. Nivolumab, a PD-1 inhibitor, is intended for patients who have been previously treated with ipilimumab (Yervoy) and, for melanoma patients whose tumors express the BRAF V600 mutation, for use after treatment with ipilimumab […]

View full entry

Tags: fda, Melanoma, News, nivolumab, opdivo, PD-1, Recurrent Melanoma, Stage IV Melanoma


December 8th, 2014

Yervoy® May be Beneficial in Uveal Melanoma

By

The first trial of the immunomodulator Yervoy® (ipilimumab) conducted in patients with uveal melanoma appears promising in according to the results of a small clinical trial presented at the recent Society of Melanoma Research (SMR) 2014 International Congress, in Zurich, Switzerland. Uveal melanoma is the most common cancer of the eye in adults, and the […]

View full entry

Tags: ipilimumab, Melanoma, News, Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma, uveal melanoma, Yervoy